Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

Rosa Izu-Belloso; I. Gainza-Apraiz; Pablo L. Ortiz‐Romero; Octavio Servitje-Bedate; R. Fernández de Misa-Cabrera; Yeray Peñate; B. Hernández‐Machín; T. Estrach-Panella; Mar Llamas‐Velasco; J.I. Yanguas-Bayona; M. Morillo-Andujar; E. Acebo-Mariñas; S. Pérez‐Gala; J.C. Armario-Hita; P. Sánchez‐Sambucety; A. Ortiz-Brugues; C. Eguren-Michelena; I. Bielsa-Marsol; A. López-Pestaña; Mar Blanes‐Martínez; M. Fernandez-Guarino; Ingrid López‐Lerma

doi:10.1016/j.ad.2023.12.007

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Izu-Belloso et al. (2024) studied this question.

synapsesocial.com/papers/68e780ddb6db6435876f44f6 https://doi.org/10.1016/j.ad.2023.12.007

View Full Paper

Ask AI

Bookmark

Share

Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

Ask about this paper

Abstract

Discussion

Cite This Study

Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading